Home MarketDivi's Laboratories Ltd.

Divi's Laboratories Ltd. Stock Info: As on 2018-05-24 15:52:29

Nse

1128.70

35.35(3.23%)
Change%
52 Week Range
532.65
29.00
1,223.00
11.00
Open1,093.10
Day's Range984.02 - 1,202.69
Value Traded (in ₹ Cr.) 50.71

Bse

1127.30

34.55(3.16%)
Change %
52 Week Range
533.10
29.00
1,220.00
11.00
Open1,092.65
Day's Range983.48 - 1,202.03
Value Traded (in ₹ Cr.) 2.10

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 138,181,232.00 52.05%
Mutual Funds/UTI 41,025,312.00 15.45%
FII 48,862,026.00 18.41%
Employee 0.00 0.00%
Public 22,366,479.00 8.43%
Government 0.00 0.00%
Others 14,195,270.00 5.35%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 4.12
Basic EPS (Rs.) 39.68
Cash EPS 44.32
BVPerShare Excl 203.75
Operating Revenue 151.58
PBDITPerShare 57.02
Dividend 10.00
NPPerShare 39.68
Current Ratio 6.16
Quick Ratio 4.24
PriceToBV 3.06
Earnings 0.06
PBDIT Margin 37.61
PBT Margin 34.49
NP Margin 26.17
Return On Assets 16.96
Retention Ratios 0.00
Parameter Mar-17 (₹ Cr.) Yoy%change
Total Income 4,099.83
Total Expenses 2,711.60
EBITDA 1,513.75
PBT 1,388.23
PAT 1,053.27
Net Income 1,053.27
More
Parameter Sep-17 (₹ Cr.) 6M % change
Total Income 1,774.67
Total Expenses 1,255.62
EBITDA 452.81
PBT 517.81
PAT 383.32
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-17 (₹ Cr.) Yoy%change
Total share capital 53.09
Net worth 5,408.91
Investments 1,639.09
Total Liability 6,210.08
Total debt 35.74
Net block 2,002.53
Total Assets 6,210.08
Parameter Sep-17 (₹ Cr.) 6M % change
Total share capital 53.09
Net worth 4,100.87
Investments 662.79
Total Liability 4,761.28
Total debt 36.68
Net block 1,590.62
Total Assets 4,761.28
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

533.05 531.95 0.21
524.95580

Abbott India Ltd.

6671.7 6587.45 1.28
65106890

Ajanta Pharma Ltd.

977.6 987 -0.95
962.351074.5

Albert David Ltd.

362.35 362.75 -0.11
356.2383.15

Alembic Ltd.

48.85 50.8 -3.84
50.254

Alembic Pharmaceuticals Ltd.

420.7 422.3 -0.38
418.5491.2

Alkem Laboratories Ltd.

1957.55 1965.35 -0.4
18882036.65
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

47.5 49.05 -3.16
46.351.55

Aarti Drugs Ltd.

530 529.15 0.16
526585

Aayush Food & Herbs Ltd.

47.7 48.1 -0.83
4355

Abbott India Ltd.

6699.95 6593.7 1.61
6465.056872.5

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-17(in ₹ Cr.)
Cash from operating activities 1,148.05
Cash from investing activities -1,134.08
Cash from financing activities -9.31
Net change in cash 4.66

Stock Held By Mutual Fund Schemes

Corporate Details

About Management

Milestones: 1990 -Divis Research Center (DRC) established. 1991-1993 -DRC successfully develops several commercial processes for intermediates and bulk actives and supplies to manufacturing majors. 1994 -Divis Research Center changes its name to Divis Laboratories Limited to reflect its growing area of operations and its plans to enter the manufacturing sector in the following year. 1995 -Manufacturing Facility (Unit-1) at Choutuppal near Hyderabad starts operations. 1997 -SGS-Yarsley of U.K certifies Divis Laboratories as ISO-9002 compliant. 1999 -European Directorate gives a "Certificate of Suitability" (CoS) for Naproxen produced at Divis Laboratories. 2000 -US-FDA inspects Divis Laboratories successfully SGS-Yarsley of U.K awards Divis the ISO 9001 Certification SGS International AG of Switzerland awards Divis the ISO-14001 Certification (for its efficient Environment Management Systems). 2001 -BVQI of London awards Divis the OHSAS-18001 Certification (for its Occupational Health and Safety Management Systems). 2002 -Divis commences the setting up of its 2nd Manufacturing Facility (Unit-2) at Chippada near Visakhapatnam. 2003 -Divis opens a new research center christened `DRC-Vizag' for fundamental research in selected niche business core segments. -Went for IPO and listed on stock exchanges BSE, NSE and HSE. -Divi's Laboratorie receives Certificate of Substantiability from the council of Europe -Appointed Mr A Narendra as Company Secretary & Compliance Officer of the company (in place of outgoing Company Secretary Mr P Sudarshan) who has joined the organization. 2004 - Divi'S Laboratories Limited has informed that the manufacturing facility of Divi's Labs at Choutuppal near Hyderabad was successfully inspected by US-FDA in May 2004. -US-FDA inspects the Choutuppal (Unit-1) for a second time. No 483. 2006 -Delists equity shares form The Hyderabad Stock Exchange Ltd (HSE), Hyderabad with effect from March 29, 2006. -US-FDA inspects the Visakhapatnam(Unit-2) for the first time. 2007 - The Company has splits its face value from Rs10/- to Rs2/-. 2008 -Third US-FDA inspection for Choutuppal(Unit-1). 2009 - Certified and Awarded for "Best Green Belt Development" - SURAKSHA PURASKAR for the year 2008 - ISO 14001: 2004 (Re-Certification) "Environment Management System" -Divi's Laboratories has given the Bonus in the Ratio of 1:1 2010 - Divis Lab - Setting up of a new Unit in SEZ at Visakhapatnam. - The Company has recommended a dividend of 300% i.e. Rs. 6/- per equity share of Rs. 2/- face value for the year ended March 31, 2010. 2011 - Divi’s Laboratories surged 3.5 per cent in early morning trade on Bombay Stock Exchange on November 2, 2011, after the announcement of healthy growth in Q2 numbers on November 1, 2011, after trading hours. - Shares of the company after opening higher at Rs 765 from previous close of Rs 759.20, rose to hit a high of Rs 785.40 on BSE, reflecting the gain of 3.5 per cent. At 11:05 AM, the stock was trading at Rs 772.85 on Bombay Stock Exchange. 2012 - Divis Laboratories Ltd has informed BSE that the Board of Directors through Circular resolution dated March 07, 2012 has decided to seek shareholders approval by postal ballot for Re-appointment and revision in remuneration of Mr. Madhusudana Rao Divi as Director-Projects of the Company. - The Company Re-appointment and revision in remuneration of Mr. Kiran S. Divi Director & President- Operations of the Company. - Enhancement of remuneration of Dr. Murali K. Divi, Chairman & Managing Director of the Company. - Enhancement of remuneration of Mr. N. V. Ramana, Executive Director of the Company. 2013 -Divis Laboratories Ltd. has recommended a dividend of 750% i.e. Rs. 15/- per equity share of Rs. 2/- face value for the year ended March 31, 2013. 2014 -Divis Laboratories Ltd. has recommended a dividend of 1000% i.e. Rs. 20/- per equity shares of Rs. 2/- face value for the year ended March 31, 2014. 2015 -Divis Laboratories Ltd has approved to give bonus shares on the eve of 25th year of formation of the Company, in the ratio of 1:1. 2016 -Divis Labs unit-2 at Chippada successfully inspected by USFDA

Registered Office

DSN SEZ Unit : Chippada Village, Bheemunipatnam Mandal,

,,,      ,

Registrar Details

Karvy Computershare Private Ltd.